Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses

Journal of Infectious Diseases

Volumn 202, Issue 2, 2010, Pages 223-233

  Singh, Rekha ^a   Rothman, Alan L ^a   Potts, James ^a   Guirakhoo, Farshad ^b   Ennis, Francis A ^a   Green, Sharone ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; JAPANESE ENCEPHALITIS VACCINE; NONSTRUCTURAL PROTEIN 3; WEST NILE VACCINE; YELLOW FEVER VACCINE; PEPTIDE FRAGMENT; VIRUS ENVELOPE PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; JAPANESE ENCEPHALITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS TITRATION; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CERCOPITHECUS; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS; FLAVIVIRUS INFECTION; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SEQUENCE HOMOLOGY; VERO CELL; VIRUS CULTURE;

AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; CONSERVED SEQUENCE; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PLAQUE ASSAY; SEQUENCE HOMOLOGY, AMINO ACID; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 77954565539     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653486     Document Type: Article

References (50)

1. Gubler D, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 5th ed. Vol 1. Philadelphia: LippincottWilliam & Wilkins, 2007:1153-1253.
2. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and Dengue viruses. Nat Med 2004; 10(12):S98-S109.
3. Solomon T. Flavivirus encephalitis. N Engl J Med 2004; 351:370-378.
4. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 2002; 33:330-342.
5. Tesh RB. Viral hemorrhagic fevers of South America. Biomedica 2002; 22(3):287-295.
6. Mukhopadhyay S, Kuhn RJ, Rossman MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005; 3:13-22.
7. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 2002; 296(1):117-124.
8. Purtha WE, Myers N, Mitaksov V, et al. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol 2007; 37(7):1845-1854.
9. + T Cells in control of West Nile Virus infection. J Virol 2004; 78(15):8312-8321.
10. Thomas SJ, Hombach J, Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009; 27(3):355-368.
11. + T cells responding to lethal West Nile virus infection. Eur J Immunol 2007; 37(7):1855-1863.
12. + T cell differentiation during viral infection. Immunity 2007; 27(3):393-405.
13. + T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000; 18:275-308.
14. Chen W, Antov LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in MHC Class I restricted T cell responses to viruses. Immunity 2000; 12:83-93.
15. + T cells display quantitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 2006; 176(5):2817-2824.
16. Selin LK, Cornberg M, Bhrem MA, et al. CD8 memory T cells: crossreactivity and heterologous immunity. Semin Immunol 2004; 16(5): 335-347.
17. Welsh RM, Rothman AL. Dengue immune response: low affinity, high febrility. Nat Med 2003; 9(7):820-822.
18. Monath TP, Myers GA, Beck RA, et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005; 33(3):131-144.
19. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 2006; 176(6):3821-3829.
20. + T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J Infect Dis 2008; 197(4):608-617.
21. + T cells using heterologous prime-boost immunization strategies. Immunol Rev 1999; 170:29-38.
22. Radosević K, Rodriguez A, Lemckert A, Goudsmit J. Heterologous prime-boost vaccination for poverty-related disease: advantages and future prospects. Expert Rev Vaccines 2009; 8(5):577-592.
23. Masopust D, Ha SJ, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 2006; 177(2):831-839.
24. Deng Y, Zhang K, Tan W, et al. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T cell responses to HCV in BALB/c mice. Vaccine 2009; 27(15):2085-2088.
25. Chambers TJ, Nestorowicz A, Mason PW, Eckels KH, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties. J Virol 1999; 73:3095-3101.
26. Pugachev KV, Guirakhoo F, Mitchell F, et al. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg 2004; 71(5):639-645.
27. Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000; 74(4):1742-1751.
28. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188(8):1213-1230.
29. Arroyo J, Miller C, Catalan J, et al. ChimeriVax-West Nile virus liveattenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78(22):12497-12507.
30. Monath TP, Liu J, Kanesa-Thasan N, et al. A live attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006; 103: 6694-6699.
31. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-1018.
32. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 ChimeriVax-DEN2 vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all. Hum Vaccin 2006; 2(2):60-67.
33. Murali-Krishna K, Ravi V, Manjunath, R. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J Gen Virol 1996; 77 (Pt 4): 705-714.
34. + T cells. J Immunol 2009; 182:4865-4873.
35. Puig-Basagoiti F, Tilgner M, Forshey B, et al. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother 2006; 50:1320-1329.
36. + CTL epitope with distinct functional profiles. J Immunol 2005; 174(4):2212-2219.
37. Konty U, Kurane I, Ennis FA. Gamma interferon augments Fcg receptor- mediated dengue virus infection of human monocytic cells. J Virol 1988; 62(11):3928-3933.
38. + T cell cross-reactive and heterologous immunity. Immunol Rev 2006; 211:164-181.
39. Lim CK, Takashi T, Kotaki A, Kurane I. Vero cell inactivatedWest Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 2008; 374(1):60-70.
40. Blattman JN, Sourdive DJ, Murali-Krishna K, Ahmed R, Altman JD. Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection. J Immunol 2000; 165:6081-6090.
41. Falk K, Rötzschke O, Deres K, Metzger J, Jung G, Rammensee HG. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 1991; 174:425-434.
42. Sigal LJ, Goebel P, Wylie DE. Db-binding peptides from influenza A virus: effect of non-anchor residues on stability and immunodominance. Mol Immunol 1995; 32(9):623-632.
43. Trojan A, Witzen M, Schultze JL, et al. Generation of cytotoxic T lymphocytes against naïve and altered peptides of human leukocyte antigen-A* 0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001; 61:4761-4765.
44. z.ast 0201-binding affinity. J Immunol 2001; 167:787-796.
45. Guy B, Barban V, Mantel N, et al. Evaluation of interferences between dengue virus serotypes in a monkey model. Am J Trop Med Hyg 2009; 80(2):302-311.
46. + T cell response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. Viral Immunol 2009; 22(3):215-219.
47. Zou H, Deem MW. Sculpting the immunological response to dengue fever by polytopic vaccination. Vaccine 2006; 24(14):2451-2459.
48. Stone JD, Chervin AS, Kranz DM. T cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 2009; 126(2):165-176.
49. Alam SM, Davis GM, Lin CM, et al. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity 1999; 10:227-237.
50. Rosette C, Werlen G, Daniels MA, et al. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity 2001; 15:59-70.